ZDNET的关键外卖
胰岛素抗药性和血压趋势来到了Fitbit空气和Fitbit边缘。
——这些新功能仅供Google健康保费用户使用。
- 新闻显示Google在发展连续的葡萄糖监测器方面有更大的健康任务。
Google刚刚给Fitbit Air和Edge增加了胰岛素抗药性和血压趋势，将这些装置超越了基本健身监测和睡眠跟踪，进入了更深层次的健康洞察。 这些新功能是Google的"健康守护者"套套装，用于像素观察和Fitbit的主动安全工具的一部分。
还有：AI健康教练订阅是骗局吗？测试Fitbit一个月后
专供Google健康保费用户使用，每年100美元订阅，让用户能够使用Google的AI健康导师
更多来自 ZDNET
其算法分析心率、活性水平、睡眠和其他衡量标准，Fitbit也会在无袖的情况下追踪你的血压模式，符合资格的 Fitbit Air 和 Fitbit Edge 用户已经磨损了5天或5天以上的设备，将在应用程序的健康标签中看到这种见解。
与血压趋势类似，胰岛素抗药性特征使用Fitbit传感器来监测代谢健康的变化。 胰岛素抗药性是2型糖尿病的先兆，可能让使用者以较少侵入性的方式洞察其胰岛素水平的变化，但比直接诊断更能指向总体趋势。
与穿透皮肤并用血液来收集代谢数据的连续葡萄糖监测器不同，胰岛素抗药性特征是通过其多模式来评估生物特征和代谢模式的。 Google根据《自然》的论文，根据其他可穿戴物收集的数据以及汇编的人口数据，对其胰岛素抗药性模型进行了培训。
我还测试了Google的"健身边缘" — — 它的突出特征也让我需要更多
一旦该特性检测出高高的胰岛素抗药性模式，便会通知用户采取额外行动。 Fitbit用户甚至可以将其Abbott CGM与Google Health App连接，用于额外的葡萄糖监测。 Google通过向更多的设备提供这些"健康卫士"的特性，而不仅仅是它的旗舰"像素观察"(Pixel Watches)，让更多的用户——具体来说是拥有一款100美元和180美元"Fitbit Air"或"Edge"的预算意识用户——能够追踪和保持一些常见而严重的健康状况。
虽然胰岛素抗药性特征离非入侵性CGM的能力还差得很远，但Google开发了跟踪胰岛素活动生物鉴别反应的多模式模型，表明该公司正接近于非入侵性现实。
非侵入性葡萄糖监测就像可穿戴技术的可折叠电话。 这个产品想法已经存在好几年了，每个技术公司都在竞相部署自己的设备，甚至史蒂夫·乔布斯也梦到人们可以使用的Apple葡萄糖监测器——不需要指刺。 有传言称Apple也为此工作了多年。
但Google可能比Apple在这一站领先了几步。 它向新的Fitbit设备部署胰岛素抗药性趋势，是它向使用算法AI而不是针和血液的CGM推进的一种方式。
本文由 AI宝库自动抓取并翻译，版权归原作者所有；如需查看原文请点下方链接。
ZDNET’s key takeaways
- Insulin resistance and blood pressure trends are coming to the Fitbit Air and Fitbit Edge.
- These new features are available for Google Health Premium users only.
- The news points at Google’s greater health mission in developing a continuous glucose monitor.
Google just added insulin resistance and blood pressure trends to the Fitbit Air and Edge, taking these devices beyond basic fitness monitoring and sleep tracking and into deeper health insights. The new features are part of Google’s “Health Guardian” suite of proactive safety tools for the Pixel Watch and Fitbit.
Also: Are AI health coach subscriptions a scam? My verdict after testing Fitbit’s for a month
They’re available solely for Google Health Premium users, a $100 annual subscription that grants users access to Google’s AI health coach, advanced sleep tracking, and a more expansive selection of health-tracking features.
More from ZDNET
While it doesn’t measure your insulin or glucose outright, its algorithm analyzes heart rate, activity level, sleep, and other metrics to show changes in metabolic health. The Fitbit will also track your blood pressure patterns without a cuff, monitor your pulse while you’re asleep or awake, and, at the end of the month, provide you with insights. Eligible Fitbit Air and Fitbit Edge users who have worn their device for five days or more will see this insight in the Health tab of the app.
Similar to blood pressure trends, the insulin resistance feature uses Fitbit sensors to monitor shifts in metabolic health. Insulin resistance is a precursor to type 2 diabetes, potentially giving users insight into changes in their insulin levels in a less invasive way, but pointing more toward overall trends than a direct diagnosis.
Unlike a continuous glucose monitor, which penetrates the skin and uses blood to gather metabolic data, the insulin resistance feature was built to assess biometric and metabolic patterns through its multimodal model. Google trained its insulin resistance model on data gathered by other wearables as well as compiled demographic data, according to its paper in Nature.
Also: I tested Google’s Fitbit Edge – its standout feature also left me wanting more
Once the feature detects elevated insulin resistance patterns, it notifies the user to take additional action. Fitbit users can even connect their Abbott CGM to the Google Health app for additional glucose monitoring. By offering these Health Guardian features to more devices than just its flagship Pixel Watches, Google is giving more users — specifically budget-conscious users who own a $100 and $180 Fitbit Air or Edge — the ability to track and stay ahead of some common and serious health conditions.
While the insulin resistance feature is nowhere near the capabilities of a non-invasive CGM, Google’s development of a multimodal model for tracking biometric responses to insulin activity suggests the company is getting closer to that non-invasive reality.
Non-invasive glucose monitoring is like the foldable phone of wearable technology. It’s a product idea that’s been around for years now, and every tech company is racing to deploy its own, with varying degrees of success and adoption. Even Steve Jobs had dreams of an Apple glucose monitor that people could use — no finger prick necessary. Rumors suggest that Apple has also been working on this for years now.
But Google might be a few steps ahead of Apple on this one. Its deployment of insulin resistance trends to new Fitbit devices is one way it is advancing toward a CGM that uses algorithmic AI instead of needles and blood.
Auto-fetched and translated by AI Gem Box. All rights belong to the original author.